AlphaCrest Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

AlphaCrest Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,910	Closed	-$1.71M	–	1112
2022 Q3	$1.71M	Sell	5,910 -3,402	-37%	-$979K	0.1%	287
2022 Q2	$2.62M	Sell	9,312 -4,303	-32%	-$1.15M	0.13%	201
2022 Q1	$3.55M	Sell	13,615 -20,120	-60%	-$4.78M	0.2%	93
2021 Q4	$7.41M	Buy	33,735 +2,115	+7%	+$411K	0.28%	49
2021 Q3	$5.74M	Sell	31,620 -2,788	-8%	-$544K	0.3%	37
2021 Q2	$6.94M	Buy	34,408 +18,021	+110%	+$3.77M	0.3%	54
2021 Q1	$3.52M	Buy	16,387 +11,898	+265%	+$2.61M	0.2%	118
2020 Q4	$1.06M	Buy	4,489 +724	+19%	+$166K	0.09%	299
2020 Q3	$1.02M	Sell	3,765 -2,049	-35%	-$565K	0.11%	251
2020 Q2	$1.69M	Buy	5,814 +2,052	+55%	+$556K	0.28%	58
2020 Q1	$895K	Buy	3,762 +918	+32%	+$211K	0.11%	318
2019 Q4	$623K	Sell	2,844 -13,138	-82%	-$2.66M	0.05%	640
2019 Q3	$2.71M	Buy	15,982 +14,007	+709%	+$2.48M	0.16%	143
2019 Q2	$362K	Sell	1,975 -1,573	-44%	-$275K	0.03%	804
2019 Q1	$653K	Buy	+3,548	New	+$655K	0.1%	359

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

AlphaCrest Capital Management's VRTX Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2022, closing a stake of 5,910 shares — an estimated $1.71M sold.

AlphaCrest Capital Management first reported a position in VRTX in Q1 2019 and held it in 15 quarters. The position peaked at $7.41M in Q4 2021. 1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

AlphaCrest Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 5,910 Vertex Pharmaceuticals shares in Q4 2022, an estimated $1.71M.
AlphaCrest Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 15 quarters.
AlphaCrest Capital Management's Vertex Pharmaceuticals position peaked at $7.41M in Q4 2021.
1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.